I'm not sure that a Phase III will be needed. They have shown great results with little to no toxic side affects. The only reason I will not rule out a phase III is because the small sample size.
Otherwise I can't believe that the OTC MMs have been able to keep this stock under control. If avg volume continues to rise say to 3-5Mill per day then I say its game over for the MM games. That type of daily volume should blow this to $1-$4 easy.
On top of that the INO volume is crazy. 1 has to think if INO is a target that the takeover participant wouldn't mind spending a little more to secure ONCS. That would keep the technology complete and bring in another revenue avenue.
Yes that article was not good. I love the fact he states their cash position from end of September when on Oct 8th or 9th they also completed an offering. That shows he didn't do any homework when writing the article. Probably just another hack job written by someone who will be paid pennies per view.
Anyway I bought in on Friday during the afterhours. This should see some serious upside during the next 12 months.
At 940 am I put in for a small 572k share purchase. It didn't fill until after 3pm. Makes me happy to know MMs were not willing to fill at will. Thinking about 10 million shares but now I'm not sure it will fill.
INO's stock appreciated well before the Roche deal took place. I believe it would be in INO's interest to acquire ONCS and their own technology soon. Regardless of this happening I think it is only a matter of time before a large fish buys both companies in one swoop. With little to no side effects there is a good chance a phase III will never happen. I will not say 100% chance of no phase III because didn't have a large population of test subjects.
No reason for Nasdaq as real OTC stocks that run can run real big. This is because MMs get out of the way. This can happen here with the anticipated news. I just worry about future dilution.
Partnerships or buyouts are very possible. All the large players probably are watching. I would think INO would try to make a $1 offer soon because it would be in their best interest. They know ONCS potential better than anyone. They licensed this technology to ONCS when they themselves were in bad shape. Buying ONCS now with multiple promising drugs/systems in mid stages is very cost effective.